{"filing":{"accession_number":"0001437749-26-033053","cik":"0001595248","ticker":"GNPX","company_name":"Genprex, Inc.","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"gnpx20261020_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926033053/gnpx20261020_8k.htm"},"events":[{"id":36582,"run_id":33729,"accession_number":"0001437749-26-033053","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"Genprex disclosed peer-reviewed research published in Mechanisms of Ageing and Development demonstrating that TUSC2—the therapeutic gene underlying its lead oncology program REQORSA®—plays a foundational role in brain health and mitochondrial function. While the study was conducted in mice and does not evaluate REQORSA as a treatment for neurodegeneration, the findings expand scientific understanding of TUSC2's biological significance beyond cancer and identify potential new therapeutic avenues in age-related cognitive disorders. This is a material operational/strategic disclosure of research supporting the scientific rationale for the company's core asset, though it does not fit neatly into a specific category (not a product approval, partnership, or regulatory milestone, but a research validation event).","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41044,"accession_number":"0001437749-26-033053","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Genprex disclosed peer-reviewed research published in Mechanisms of Ageing and Development demonstrating that TUSC2—the therapeutic gene underlying its lead oncology program REQORSA®—plays a foundational role in brain health and mitochondrial function. While the study was conducted in mice and does not evaluate REQORSA as a treatment for neurodegeneration, the findings expand scientific understanding of TUSC2's biological significance beyond cancer and identify potential new therapeutic avenues in age-related cognitive disorders. This is a material operational/strategic disclosure of research supporting the scientific rationale for the company's core asset, though it does not fit neatly into a specific category (not a product approval, partnership, or regulatory milestone, but a research validation event).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T11:03:41.526903+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41044,"accession_number":"0001437749-26-033053","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Genprex disclosed peer-reviewed research published in Mechanisms of Ageing and Development demonstrating that TUSC2—the therapeutic gene underlying its lead oncology program REQORSA®—plays a foundational role in brain health and mitochondrial function. While the study was conducted in mice and does not evaluate REQORSA as a treatment for neurodegeneration, the findings expand scientific understanding of TUSC2's biological significance beyond cancer and identify potential new therapeutic avenues in age-related cognitive disorders. This is a material operational/strategic disclosure of research supporting the scientific rationale for the company's core asset, though it does not fit neatly into a specific category (not a product approval, partnership, or regulatory milestone, but a research validation event).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T11:03:41.526903+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-10-21"}]}